| abstract |
The specification relates to methods for treating a neurodegenerative disease such as multiple sclerosis by administering to a subject in need an EphA4 antagonist or an EphA4 ligand antagonist. The antagonist may be a soluble EphA4 or EphA4-binding ephrin or a functional variant thereof such as an EphA4-Fc or an ephrin A5-Fc. The antagonist may be an antibody or an antigen binding antibody fragment, a nucleic acid, polypeptide, peptide, or organic molecule that binds to EphA4 or an EphA4-ligand or a nucleic acid encoding same and downregulates its activity. |